PDS Biotech Logo.png
PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results
28 mars 2023 07h30 HE | PDS Biotechnology Corporation
Successful meeting with FDA to discuss registrational pathway for triple combination of PDS0101, PDS0301, and a commercial immune checkpoint inhibitor100% (9/9) clinical response (>60% tumor...
proton-therapy-market-size.jpg
The Worldwide Proton Therapy Industry is Expected to Reach $963.6 Million by 2028
12 janv. 2023 04h43 HE | Research and Markets
Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "Global Proton Therapy Market Size, Share & Industry Trends Analysis Report By Product Type, By Indication (CNS Cancer, Prostate Cancer, Head &...
radiation-oncology-market-size.jpg
Outlook on the Radiation Oncology Global Market to 2028 - Featuring Varian Medical Systems, Ion Beam Applications, Elekta and Accuray Among Others
11 janv. 2023 07h58 HE | Research and Markets
Dublin, Jan. 11, 2023 (GLOBE NEWSWIRE) -- The "Global Radiation Oncology Market Size, Share & Industry Trends Analysis Report By Application, By Type (External Beam Radiation Therapy and...
new logo.jpg
Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer
04 janv. 2023 08h00 HE | Immutep Limited
SYDNEY, AUSTRALIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3...
PDS Biotech Logo.png
PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer
15 déc. 2022 08h00 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
DI 400 x 400  copy jpeg.jpg
Head And Neck Cancer Therapeutics Market Is Estimated To Grow At CAGR Of 8.5 %, 2022-2028 | Latest Industry Coverage By Douglas Insights
08 nov. 2022 05h08 HE | Douglas Insights
Isle Of Man, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Douglas Insights has made the newest addition to their comparison engine. Head and neck cancer therapeutics market research reports can now be compared...
PDS Biotech Logo.png
PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable
27 oct. 2022 08h00 HE | PDS Biotechnology Corporation
Jared Weiss, MD, Lead Investigator for the VERSATILE-002 clinical trial combining PDS0101 and KEYTRUDA®, presents interim data from the study Combination shows potential to achieve oncologists’ goals...
Kura Oncology Logo
Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma
26 oct. 2022 07h30 HE | Kura Oncology, Inc.
– First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent HNSCC – – Preclinical data support potential to address ~45% of HNSCC tumors...
PDS Biotech Logo.png
PDS Biotech Chief Medical Officer Dr. Lauren V. Wood to Address 2022 International Head and Neck Conference
25 oct. 2022 08h00 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
Global Radiation Oncology Market
$10.8 Billion Worldwide Radiation Oncology Industry to 2027 - Featuring Accuray, Canon, Elekta and Hitachi Among Others
28 sept. 2022 04h18 HE | Research and Markets
Dublin, Sept. 28, 2022 (GLOBE NEWSWIRE) -- The "Radiation Oncology Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...